StreetInsider.com News Articles

Pulmonx Corp. (LUNG) PT Lowered to $5 at Canaccord

Thu, 05 Mar 2026 06:44:17 -0500

Canaccord analyst John Young lowered the price target on Pulmonx Corp. (NASDAQ: LUNG) to $5.00 (from $6.00) while maintaining a Buy rating.

Form 8-K Pulmonx Corp For: Mar 02

Thu, 05 Mar 2026 06:02:00 -0500

si-local-file:///var/storage/secattach/20260305/26114413.html

Form 8-K Pulmonx Corp For: Mar 02

Thu, 05 Mar 2026 06:02:00 -0500

si-local-file:///var/storage/secattach/20260305/26114413.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Radhakrishnan Srikanth

Wed, 04 Mar 2026 19:08:00 -0500

si-local-file:///var/storage/secattach/20260304/26113398.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Radhakrishnan Srikanth

Wed, 04 Mar 2026 19:08:00 -0500

si-local-file:///var/storage/secattach/20260304/26113398.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: French Glendon E. III

Wed, 04 Mar 2026 19:06:00 -0500

si-local-file:///var/storage/secattach/20260304/26113392.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: French Glendon E. III

Wed, 04 Mar 2026 19:06:00 -0500

si-local-file:///var/storage/secattach/20260304/26113392.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Rose Geoffrey Beran

Wed, 04 Mar 2026 19:04:00 -0500

si-local-file:///var/storage/secattach/20260304/26113385.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Rose Geoffrey Beran

Wed, 04 Mar 2026 19:04:00 -0500

si-local-file:///var/storage/secattach/20260304/26113385.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Lehman David Aaron

Wed, 04 Mar 2026 19:02:00 -0500

si-local-file:///var/storage/secattach/20260304/26113381.html

Form 4 Pulmonx Corp For: Mar 02 Filed by: Lehman David Aaron

Wed, 04 Mar 2026 19:02:00 -0500

si-local-file:///var/storage/secattach/20260304/26113381.html

Pulmonx Corporation (LUNG) Tops Q4 EPS by 14c

Wed, 04 Mar 2026 16:28:22 -0500

Pulmonx Corporation (NASDAQ: LUNG) reported Q4 EPS of ($0.25), $0.14 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $22.59 million versus the consensus estimate of $23.21 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

Form 8-K Pulmonx Corp For: Mar 04

Wed, 04 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260304/26111166.html

Form 8-K Pulmonx Corp For: Mar 04

Wed, 04 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260304/26111166.html

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 16:06:00 -0500

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Recent Highlights

Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis
Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 16:06:00 -0500

Recent Highlights

Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis
Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 16:06:00 -0500

Recent Highlights

Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis
Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 16:06:00 -0500

Recent Highlights

Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis
Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period

Pulmonx closes $60 million credit facility with Perceptive Advisors

Wed, 04 Mar 2026 16:05:37 -0500

Pulmonx Corporation (NASDAQ: LUNG) closed a five-year credit facility for up to $60 million with Perceptive Advisors, the company announced March 4.

The facility includes an initial $40 million term loan drawn at closing to refinance existing debt, plus an option to draw an additional $20 million through the end of 2027, subject to achieving certain revenue milestones. The new facility is interest-only until maturity in 2031 and bears interest at one-month Term SOFR plus 7.0%, with a 3.75% floor. The company can pay 2.0% of the interest in-kind for three years following closing.

"This new debt facility immediately strengthens our capital

Pulmonx closes $60 million credit facility with Perceptive Advisors

Wed, 04 Mar 2026 16:05:37 -0500

Pulmonx Corporation (NASDAQ: LUNG) closed a five-year credit facility for up to $60 million with Perceptive Advisors, the company announced March 4.

"This new debt facility immediately strengthens our capital

Pulmonx closes $60 million credit facility with Perceptive Advisors

Wed, 04 Mar 2026 16:05:37 -0500

Pulmonx Corporation (NASDAQ: LUNG) closed a five-year credit facility for up to $60 million with Perceptive Advisors, the company announced March 4.

"This new debt facility immediately strengthens our capital

Pulmonx closes $60 million credit facility with Perceptive Advisors

Wed, 04 Mar 2026 16:05:37 -0500

Pulmonx Corporation (NASDAQ: LUNG) closed a five-year credit facility for up to $60 million with Perceptive Advisors, the company announced March 4.

"This new debt facility immediately strengthens our capital

Pulmonx closes $60 million credit facility with Perceptive Advisors

Wed, 04 Mar 2026 16:05:10 -0500

Pulmonx Corporation (NASDAQ: LUNG) closed a five-year credit facility for up to $60 million with Perceptive Advisors, the medical device company announced March 4.

The facility includes an initial $40 million term loan drawn at closing to refinance existing debt, plus an option to draw an additional $20 million through the end of 2027, subject to achieving certain revenue milestones. The new facility is interest-only until maturity in 2031 and bears interest at one-month Term SOFR plus 7.0%, with a 3.75% floor. The company can elect to pay 2.0% of the interest "in-kind" for three years following closing.

"This new debt facility

Pulmonx Announces Closing of up to $60 Million Credit Facility

Wed, 04 Mar 2026 16:05:00 -0500

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors.

The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company’s existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027,

Pulmonx Announces Closing of up to $60 Million Credit Facility

Wed, 04 Mar 2026 16:05:00 -0500

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital